Events

EASL – The International Liver Congress 2017

19-23 April, 2017

Amsterdam, The Netherlands

The International Liver Congress™ (ILC) is the annual meeting of the European Association for the Study of the Liver. It is held in April every year.

https://ilc-congress.eu/

poster 170419-Poster-EASL-2017-ENYO-PHARMA-FINAL

Read more »

Asian Pacific Association for the Study of the Liver – APASL Annual Meeting 2017

February 15-19, 2017

Shangai, China

APASL annual meeting has grown as the leading conference focusing on remarkable progress in liver disease, aimed to provide the latest scientific and evidence-based research result that will be applicable to the everyday clinical practice. It provides an excellent opportunity to share and exchange experiences especially from the view of Asian Pacific countries. These elements are essential to pave a way for better development of Hepatology.

Read more »

J.P. Morgan 35th Annual Healthcare Conference

January 09-13, 2017

San Francisco, CA, USA

Jacky Vonderscher will be at San Francisco during the J.P. Morgan conference.

Read more »

The Liver Meeting 2016

November 11-15, 2016

Boston, MA, USA

More than 9,500 hepatologists and hepatology health professionals from across the nation and around the world will gather at The Liver Meeting® to exchange the latest liver diseases research, discuss treatment outcomes, and interact with colleagues at the annual must-attend even in the science and practice of hepatology.

http://www.aasld.org/events-professional-development/liver-meeting%C2%AE-2016

Read more »

AASLD/EASL HBV Treatment Endpoints Workshop

September 08-09, 2016

Alexandria, VA, USA

AASLD and EASL possess the expertise in chronic hepatitis B and D to bridge the current knowledge gaps that regulatory and pharmaceutical industry has identified as important issues hampering development of novel therapeutic agents for chronic hepatitis B and D.

This workshop will bring together the academic, regulatory and pharmaceutical communities to discuss therapeutic endpoints, trial designs and appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.

Read more »